<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366002">
  <stage>Registered</stage>
  <submitdate>20/03/2014</submitdate>
  <approvaldate>26/03/2014</approvaldate>
  <actrnumber>ACTRN12614000328673</actrnumber>
  <trial_identification>
    <studytitle>Pharmacokinetics of Oxypurinol in Patients on Dialysis</studytitle>
    <scientifictitle>An observational study of oxypurinol pharmacokinetics in haemodialysis patients treated with allopurinol</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <healthcondition>Renal impairment</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with gout already receiving 100mg of allopurinol will be recruited from the haemodialysis unit. They will be observed over a 48 hour period that includes one dialysis cycle and two allopurinol dose intervals. On the first day, blood samples will be taken hourly prior to, during, and post-dialysis up until the first 100mg dose of allopurinol. The first blood sample will be taken directly prior to the start of dialysis and then will be taken hourly for 6 hours. The allopurinol will be taken directly following the last blood sample (6 hours after the start of dialysis). On the second day, a second 100mg dose of allopurinol will be given and eight blood samples will be taken at set intervals throughout the day. The first sample will be taken prior to the allopurinol dose, and the remaining samples will be taken 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, and 6 hours after the allopurinol dose. A final blood sample will be taken at 48 hours (post study commencement).</interventions>
    <comparator>No control/comparison treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Allopurinol and oxypurinol plasma area under the concentration time curves (trend across time in concentration). Laboratory analysis of the blood samples taken will be used to determine blood concentrations of allopurinol and oxypurinol, and area under the curve concentrations will be calculated using the trapezoidal method.</outcome>
      <timepoint>0 - 48 hours from dialysis commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peak and trough concentrations at steady state will be assessed via laboratory analysis of the blood samples taken.</outcome>
      <timepoint>0 - 48 hours from dialysis commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must be receiving haemodialysis, must be diagnosed with gout, and must be already receiving 100mg of allopurinol daily.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Data will be reported as means and changes as mean difference. Allopurinol and oxypurinol concentration area under the curve (AUC) will be calculated using the trapezoidal method. Assuming a standard deviation of 30% in oxypurinol AUC, a sample of six subjects will allow estimation of the mean AUC with a margin of error of 32%</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2014</anticipatedstartdate>
    <actualstartdate>26/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/09/2014</actualenddate>
    <samplesize>6</samplesize>
    <actualsamplesize>6</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Lisa Stamp</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
University of Otago Christchurch
PO Box 4345
Christchurch 8140
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Ross Bailey Nephrology Trust
</fundingname>
      <fundingaddress>23 Ennerdale Row
Westmorland
Christchurch 8025
Canterbury</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This observational study will track allopurinol and oxypurinol serum concentrations in haemodialysis patients with allopurinol-treated gout across a 48 hour period in order to determine the pharmacokinetics of oxypurinol (the active metabolite of allopurinol) in this particular population. The results will provide insight on the efficacy of current allopurinol dosing strategies in patients with gout on haemodialysis.</summary>
    <trialwebsite />
    <publication>Wright DFB, Doogue MP, Barclay ML, Chapman PT, Cross NB, Irvine JH, Stamp LK. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol 2016 In press</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The University of Otago Human Ethics Committee (Health)</ethicname>
      <ethicaddress>Academic Committees Office
Ground Floor, Rm G22
Clocktower Building, Leith Street
University of Otago
North Dunedin
Dunedin 9016</ethicaddress>
      <ethicapprovaldate>14/04/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>31/03/2014</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago Christchurch
PO Box 4345
Christchurch 8140
New Zealand</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 364 0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago Christchurch
PO Box 4345
Christchurch 8140
New Zealand</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 364 0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago Christchurch
PO Box 4345
Christchurch 8140
New Zealand</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 364 0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago Christchurch
PO Box 4345
Christchurch 8140
New Zealand</address>
      <phone>+64 3 364 0253</phone>
      <fax>+64 3 364 0935</fax>
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>